U.S., Dec. 2 -- ClinicalTrials.gov registry received information related to the study (NCT07256015) titled 'Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy' on Aug. 28.
Brief Summary: The purpose of this study is to characterize the real-life experience of patients with moderate/severe psoriasis receiving deucravacitinib treatment, in terms of efficacy, safety, and health-related quality of life (HRQoL) in Italy
Study Start Date: Aug. 05
Study Type: OBSERVATIONAL
Condition:
Psoriasis
Intervention:
DRUG: Deucravacitinib
According to the product label
Recruitment Status: RECRUITING
Sponsor: Bristol-Myers Squibb
Disclaimer: Curated by HT Syndication....